This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.
NICE has produced a COVID-19 rapid guideline on interstitial lung disease. It recommends changes to usual practice to maximise the safety of patients and protect staff from infection during the COVID-19 pandemic.
In May 2017, recommendation 1.5.11 was amended to add a link to the NICE technology appraisal on nintedanib for the treatment of idiopathic pulmonary fibrosis, and two outdated research recommendations were removed.
This guideline includes recommendations on:
Who is it for?
- Healthcare professionals
- Commissioners and providers
- Adults with suspected or diagnosed idiopathic pulmonary fibrosis and their families and carers
Is this guideline up to date?
We checked this guideline in May 2017. We found no new evidence that affects the recommendations in this guideline.
Guideline development process
This guideline was previously called idiopathic pulmonary fibrosis: the diagnosis and management of suspected idiopathic pulmonary fibrosis.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.